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Abstract: Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one 
of the most widely utilized classes of cancer therapeutics. While highly effective, the clinical 
applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal 
pharmacokinetic properties. Therefore, one of the key research areas in oncology has been to 
develop novel platinum analog drugs and engineer new platinum drug formulations to improve 
the therapeutic ratio further. Such efforts have led to the development of platinum analogs 
including nedaplatin, heptaplatin, and lobaplatin. Moreover, reformulating platinum drugs using 
liposomes has resulted in the development of L-NDPP (Aroplatin™), SPI-77, Lipoplatin™, 
Lipoxal™, and LiPlaCis®. Liposomes possess several attractive biological activities, including 
biocompatibility, high drug loading, and improved pharmacokinetics, that are well suited for 
platinum drug delivery. In this review, we discuss the various platinum drugs and their delivery 
using liposome-based drug delivery vehicles. We compare and contrast the different liposome 
platforms as well as speculate on the future of platinum drug delivery research.
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Introduction
Platinum-based chemotherapy is one of the most widely used classes of cancer 
therapeutics. Today, there are three platinum chemotherapeutics approved by the US 
Food and Drug Administration, cisplatin, carboplatin, and oxaliplatin. Together, these 
drugs are used to treat a wide variety of cancers, including non-small and small cell 
lung, breast, colorectal, gastric, esophageal, testicular, cervical, and ovarian cancers, 







described in the 1840s, its ability to inhibit cell division (in Escherichia coli) was not 
discovered until 1965.2 Subsequent clinical development of cis-dichloro-diammine-
platinum (II), or cisplatin, eventually led to its approval for the treatment of testicular 
and ovarian cancers in 1978.1 The efficacy of cisplatin in testicular cancer was dramatic, 
with improvement in the cure rate from 5%–10% to 75%–80%.3 Following the clini-
cal development of cisplatin, carboplatin was developed in the 1980s and oxaliplatin 
was developed in the 1990s. Carboplatin is used to treat similar types of cancers as 
cisplatin, although its toxicity, especially nephrotoxicity, is much lower than that of 
cisplatin. Oxaliplatin, on the other hand, has been shown to be effective against most 
gastrointestinal cancers, including colorectal, pancreatic, and gastric cancers.4
The mechanism of action of platinum chemotherapeutics is through DNA damage.5 















]2+ species after being internalized into cells. The more reactive 





platinum species then bind to their primary biological target, 
DNA, by forming coordination bonds with purine bases 
at the N7 positions. Such a reaction results in primarily 
1,2-intrastrand or 1,3-intrastrand crosslinks and few inter-
strand crosslinks or adducts.6 These adducts can cause 
bending of the DNA duplex and facilitate binding of various 
proteins, such as high-mobility group box proteins. Protein-
bound DNA adducts induce a number of cellular responses, 
including cell cycle arrest, inhibition of DNA replication and 
the transcription process, and cell apoptosis and necrosis. 
Cisplatin-bound DNA can also be recognized by repair pro-
teins, such as xeroderma pigmentosum group A, xeroderma 
pigmentosum group F, and DNA excision repair protein 
ERCC1, leading to lesion removal and DNA recovery.7,8 
Although the exact mechanisms and pathways that lead to 
cell death still require further investigation, the nucleotide 
excision repair pathway and several signal transduction path-
ways which control the ultimate fate of tumor cells, includ-
ing those of the AKT, c-ABL, p53, and mitogen-activated 
protein/Jun N-terminal kinase/ extracellular signal-regulated 
kinase pathways, are well documented and summarized in 
the literature.9
Despite being one of the most effective classes of che-
motherapeutics, platinum drugs do have several significant 
shortcomings. First, all of the platinum chemotherapeutics 
are neurotoxic. The toxicity to the peripheral nervous system 
is one of the key dose-limiting toxicities.10 All three drugs 
also have relatively short blood circulation times, resulting in 
suboptimal pharmacokinetics. For cisplatin, nephrotoxicity 
as well as nausea and vomiting have significantly limited 
its clinical use.11 Although carboplatin has less toxicity than 
cisplatin, it is also much less potent.4,12 Myelotoxicity is also 
more profound with carboplatin, which is a dose-limiting 
toxicity.13 Because of these limitations, there has been 
strong interest in the development of novel platinum-based 
therapeutics to not only lower toxicity but also improve 
therapeutic efficacy. Two main strategies are employed. One 
is to develop new platinum analog drugs and the other is to 
utilize drug delivery technologies to engineer novel platinum 
drug formulations.14
Over the past several decades, researchers have developed 
over 3,000 platinum analogs or formulations. Unfortunately, 
only about 35 compounds exhibit adequate biological and 
pharmacologic activity to justify further preclinical and 
clinical investigations.12 Besides carboplatin and oxalipla-
tin, several other platinum analogs have been approved or 
entered clinical trials in some countries (structures are shown 
in Table 1).15 Nedaplatin has been registered in Japan for the 
treatment of head and neck, testicular, lung, ovarian, cervical, 
and non-small cell lung cancers. Heptaplatin (SKI2053R), 
which shows less anticancer activity than cisplatin in gastric 
cancer, has also been approved in South Korea because of its 
decreased toxicity profile. Lobaplatin has been used to treat 
chronic myelogenous leukemia and inoperable metastatic 
breast and small cell lung cancer in the People’s Republic 
of China.
Liposomal nanocarriers  
in drug delivery
Another strategy to improve the platinum drugs has been 
to improve the delivery of platinum therapeutics to tumors 
by use of nanoparticle drug delivery technology. A key 
challenge in cancer therapy is to deliver anticancer drugs 
and other chemotherapeutics selectively to tumors while 
minimizing accumulation in normal tissues. Such targeted 
delivery can improve therapeutic efficacy while reducing 
toxicity. Although such differential drug delivery is generally 
not possible with small molecular drugs, nanocarrier-based 
delivery can overcome this challenge via the enhanced per-
meability and retention effect.16,17 A distinct feature of tumor 
tissue compared with normal tissue is its rapid formation of 
vasculature triggered by vascular endothelial growth factor 
and other growth factors overexpressed in various cancer-
ous cells. These newly formed vessels do not have a smooth 
muscle layer so are defective and have a wider lumen, leading 
to irregular and leaky boundaries. The other key feature of 
tumor tissue is dysfunctional lymphatic drainage, resulting 
in ineffective clearance of extravascular proteins, particles, 
and white blood cells.18 Due to their large size, nanocarriers 
are not able to penetrate through the normal vasculature, but 
can penetrate through the leaky vasculature around tumor 
regions. Together with ineffective lymphatic drainage of 
tumor tissues, differential delivery/accumulation could be 
realized.19 Thus, incorporation of small molecular drugs into 
a nanoplatform could lead to improved efficacy due to their 
favorable pharmacokinetic profiles.
Liposomes were engineered in 1965,20 and were soon 
appreciated by pioneers such as Gregory Gregoriadis as 
promising drug delivery vehicles.21 Liposomes are spherical 
vesicles with an aqueous interior surrounded by one or more 
concentric bilayers (called lamellae) of phospholipids with a 
diameter ranging from 30 nm to several microns. Liposomes 
can be divided into several subtypes according to their size 
and layered structures. Multilamellar liposomes usually 
have a diameter ranging from 500 to 10,000 nm, while small 
unilamellar liposomes normally have a diameter smaller 
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than 50 nm and large unilamellar liposomes have a diameter 
greater than 50 nm. Liposomes are formed when a thin 
lipid film is hydrated with aqueous buffer solution, and are 
typically sonicated or repeatedly extruded through a 100 nm 
polycarbonate membrane to reduce their size and narrow 
their size distribution to afford small or large unilamellar 
liposomes, respectively.22 The physical and chemical proper-
ties of liposomes, such as surface charge, size, and stability, 
can be tuned using different lipid compositions. For instance, 
cationic, neutral, or anionic lipids can be used to control the 
surface charge of liposomes.23 Unsaturated phosphatidylcho-
line from natural sources (egg or soybean) generally produces 
less stable liposomes when compared with liposomes con-
structed using saturated phospholipids with long acyl chains, 
such as dipalmitoylphosphatidylcholine. Liposomes are bio-
compatible and can encapsulate hydrophilic and hydrophobic 
pharmaceutical agents in their internal water compartment 
and membrane, respectively. Encapsulation of hydrophobic 
drugs inside liposomes significantly increases their solubility 
in aqueous solution. The size, charge, and surface properties 
of liposomes that influence the pharmacokinetic profile of 
the encapsulated drug can be easily manipulated by add-
ing other ingredients to the lipid mixture before liposome 
preparation and/or by altering preparation parameters.24 It 
is thus possible to prolong the half-life of a cytotoxic drug 
in the systemic circulation and alter its biodistribution pat-
tern, leading to elevated accumulation in tumor tissue and a 
decreased dose to normal tissues. Formulation of therapeu-
tics with liposomes can significantly reduce their side effect 
profile by avoiding non-targeted systemic drug exposure in 
the body. Upon accumulation at tumor sites, liposomes can 
also provide a unique opportunity to facilitate drug uptake 
into targeted cells or even localize the drugs to specific cel-
lular compartments.
The efficacy of liposomal drugs has been further enhanced 
using a number of innovative strategies, such as remote 
drug loading,25–27 extrusion for homogeneous size,28 long-
circulating (PEGylated) liposomes,29,30 triggered-release 
liposomes,31–34 and ligand-targeted liposomes.35–37 These 
advanced techniques have indeed led to several liposomal 
Table 1 Platinum-based anticancer drugs used in the clinic
Molecular formula  
and structure
Manufacturer/distributor Dose-limiting toxicity Clinical status and indications
Cisplatin H6Cl2N2Pt Generic Nephrotoxicity Approved worldwide 
(sarcomas, small cell lung cancer, 
ovarian cancer, lymphomas, and 
germ cell tumors)
Carboplatin C6H12N2O4Pt Generic Myelosuppression Approved worldwide 
(ovarian carcinoma, lung, head and 
neck cancers)
Oxaliplatin C8H14N2O4Pt Sanofi S.A., Paris, France Neurotoxicity Approved worldwide 
(colorectal cancer, advanced gastric 
and ovarian cancers)
Nedaplatin C2H8N2O3Pt Shionogi Pharmaceuticals,  
Osaka, Japan
Myelosuppression Approved in Japan (head and neck, 
lung small cell, bladder, ovary, 
esophagus and cervix cancer)




Approved in Korea (gastric cancer)
Lobaplatin C9H18N2O3Pt Asta-Medica GmbH,  
Dresden, Germany
Thrombocytopenia Approved in the People’s Republic 
of China (chronic myelogenous 
leukemia, inoperable, metastatic 
breast, small cell lung cancer)





formulations in clinical use, with AmBisome® (Astellas 
Pharma US Inc, Northbrook, IL, USA) and Doxil® (Johnson 
and Johnson, New Brunswick, NJ, USA) being the most suc-
cessful examples. Doxil, a pegylated liposomal formulation 
of doxorubicin, is the first liposomal anticancer formulation 
approved by the US Food and Drug Administration. In 
human studies, Doxil was found to have pharmacokinetics 
dramatically different to those of doxorubicin. Doxil has a 
half-life of approximately 90 hours, whereas doxorubicin has 
an initial distribution half-life of approximately 5 minutes 
followed by a terminal half-life of 20–48 hours. The area 
under the concentration-time curve (AUC) after a dose of 
50 mg/m2 is about 300-fold greater with Doxil than with 
doxorubicin. More importantly, as the very first proof of 
the enhanced permeability and retention effect observed in 
humans, Doxil was found to accumulate preferentially in 
tumor tissue through passive targeting.38 The differential 
pharmacokinetic profiles between Doxil and doxorubicin 
also led to differing toxicity profiles. Doxil has significantly 
reduced cardiotoxicity, which is a dose-limiting toxicity 
using doxorubicin.39 On the other hand, Doxil causes more 
pronounced palmar-plantar erythrodysesthesia (hand-foot 
syndrome) than doxorubicin.40 The lower cardiotoxicity of 
Doxil is significant, because it allows prolonged and repeated 
treatments with Doxil that were previously not possible with 
doxorubicin. In addition to optimized biodistribution, tumor 
accumulation, and reduced cardiac toxicity, superior efficacy 
was observed in Kaposi’s sarcoma associated with acquired 
immune deficiency syndrome and recurrent ovarian cancer, 
and equivalent efficacy was observed in metastatic breast 
cancer and multiple myeloma.41 The most recent liposomal 
drug to be approved (in August 2012) by the US Food and 
Drug Administration is Marqibo® (Talon Therapeutics Inc, 
South San Francisco, CA, USA), a liposomal formula-
tion of vincristine for treatment of relapsed Philadelphia 
chromosome-negative acute lymphoblastic leukemia.42
Clinically evaluated liposomal 
formulations for platinum  
drug delivery
In this section, we review several liposome particles that have 
been evaluated clinically (see Table 2). We compare their 
lipid compositions, physical properties, loading methods, and 
drug-to-lipid ratios. We also discuss their pharmacokinetics, 
biodistribution, toxicity profiles, and therapeutic efficacy, 
both in preclinical animal models and in patients.
L-NDDP (Aroplatin™, Antigenics Inc, Lexington, 
MA, USA) was the first liposomal formulation studied 
in the clinic for the delivery of a cisplatin analog (cis-
bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane 
platinum II, NDDP). Multilamellar liposomes encapsulat-
ing NDDP are formed after reconstitution using a mixture 
of 1,2- dimyristoylphosphatidylcholine (DMPC) and 1,2-
 dimyristoylphosphatidylglycerol (DMPG) lipids with acidi-
fied saline solution.4 Preclinical data showed that L-NDDP had 
a dramatically different biodistribution from that of NDDP, 
with accumulation of platinum in major organs, such as the 
liver, spleen, and lymph nodes.43,44 In a preclinical toxicology 
and antitumor activity study, it was found that L-NDDP did 
not induce nephrotoxicity, but myelosuppression was the 
Table 2 Clinically evaluated liposomal formulations of platinum drugs
Formulation L-NDDP SPI-77 Lipoplatin Lipoxal LiPlaCis
encapsulated drug NDDP Cisplatin Cisplatin Oxaliplatin Cisplatin
Lipid composition DMPC/DMPG HSPC/cholesterol/
DSPe-PeG2000
HSPC/DPPG/DSPe-PeG2000 NA DSPC/DSPG/ 
DSPe-PeG2000
Particle size 1–5 μm 110 nm 110 nm NA NA
Drug-to-lipid weight ratio 1:15 1:70 1:10 NA NA
Half-life in animals (hours) NA 16 7 NA NA
Half-life in humans (hours) t1/2α, 0.8–21 min 
t1/2β, 14–36
80–145 60–117 24–35 t1/2α, 3–5.5 
t1/2β, 80–141
MTD (mg/m2) 312.5 420 300 300 120
Clinical status Phase II Phase II Phase II, III Phase I Phase I
Indications Colorectal cancer,  
malignant pleural  
mesothelioma
Ovarian, non-small  
cell lung, and head  
and neck cancer
Pancreatic cancer, head and neck  
cancer, mesothelioma, breast,  





References 43–50 52–58 59–66 67 68
Abbreviations: MTD, maximum tolerated dose; NDDP, cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II); DMPC, 1,2-dimyristoyl-sn-glycero-3-
phosphocholine; DMPG, 1,2-dimyristoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt); HSPC, hydrogenated soy phosphatidylcholine; DSPe-PeG2000, 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt); DPPG, 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt); NA, not 
available; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DSPG, 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt); min, minutes.
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major toxicity in mice. However, in canine models, L-NDDP 
also caused diffuse hemorrhagic syndrome.45–47 L-NDDP was 
found to be more active against liver and spleen metastases 
of M5076 reticulosarcoma and RAW 117 H-10 lymphoma in 
mice.48 A Phase I study of L-NDDP was performed using a 
single intravenous injection every 4 weeks.49 The maximum 
tolerated dose of L-NDDP was found to be 312.5 mg/m2 and 
the dose-limiting toxicity to be myelosuppression. A two-
compartment pharmacokinetic model was found at lower 
doses but a single-compartment model at the maximum toler-
ated dose, suggesting that saturation occurs in the organs of 
the reticuloendothelial system. A Phase II study explored the 
antitumor activity and tolerability of L-NDDP in patients with 
refractory advanced colorectal carcinoma.50 The response was 
modest, with 5.6% having a partial response, 16.7% achieving 
stable disease, and 77.8% developing disease progression. 
L-NDDP was found to be well tolerated, and 9/20 patients 
(45%) were able to receive an escalated dose of 375 mg/m2 
during the course of their treatment.
Studies using non-PEGylated multilamellar DMPC/
DMPG liposomes showed accumulation of these particles 
in the liver, which limits their clinical utility. In order to 
avoid particle uptake by organs of the reticuloendothelial 
system, Mori et al formulated NDDP-containing unilamellar 
 phosphatidylcholine/cholesterol-based liposomes with either 
monosialoganglioside (G
M1
) or polyethylene glycol (PEG)-
phosphatidylethanolamine as the surface coating.51 Indeed, 
these long-circulating NDDP-containing liposomes showed 
an approximately three-fold increase in tumor accumula-
tion as compared with conventional  phosphatidylcholine/
cholesterol-based liposomes. In vitro cytotoxicity studies 
using RIF-1 fibrosarcoma tumor cells showed that the 
presence of PEG-phosphatidylethanolamine, but not G
M1
, 
significantly enhanced the cytotoxicity of liposomal NDDP. 
In an in vivo RIF-1 tumor model in mice, a significant reduc-
tion in tumor growth rate was observed when NDDP was 
formulated in phosphatidylcholine/cholesterol/PEG3000/
phosphatidylethanolamine liposomes. These results indicate 
the potential utility of long-circulating NDDP-containing 
liposomes for cancer treatment.
SPI-77 is a formulation of sterically stabilized, long-
circulating liposomes encapsulating cisplatin. Unlike cis-
platin, which has two-compartment pharmacokinetics with 
linear elimination, the pharmacokinetics of SPI-77 are best 
characterized according to a one-compartment model with 
nonlinear elimination. The half-life was estimated to be 
16 hours in mice, compared with cisplatin which has a half-
life of 0.24 hours. In addition to a longer blood circulation 
time, SPI-77 exhibits a 60-fold larger plasma AUC, three-fold 
higher peak plasma levels, a four-fold reduction in the amount 
of platinum delivered to the kidneys, and a 28-fold higher 
tumor AUC compared with cisplatin.52 SPI-77 was also 
shown to be more effective and better tolerated than free 
cisplatin in a variety of treatment schedules and cumulative 
doses in C26 and Lewis lung tumor xenograft models.52
Despite its superior pharmacokinetic properties, SPI-77 
did not demonstrate enhanced therapeutic efficacy over cis-
platin in preclinical experiments in a separate study of M-109 
lung carcinoma, J-6456 lymphoma, and A-375 melanoma.53 
In vitro release experiments showed that less than 10% of 
cisplatin was released from the liposomes, and a cytotoxic-
ity assay also indicated reduced cytotoxic activity of SPI-77 
in vitro when compared with cisplatin. It is believed that 
SPI-77 is delivered to tumor sites, but with extremely slow 
release kinetics. Similar results were obtained by Zamboni 
et al using microdialysis technology, showing that more 
SPI-77 distributes into tumors but releases less platinum into 
the extracellular tumoral fluid and forms fewer platinum-
DNA adducts than cisplatin.54
Not surprisingly, SPI-77 was shown to have a long 
circulation time, with a plasma circulation half-life as long 
as 145 ± 107 hours in patients given a 420 mg/m2 dose in a 
Phase I study.55 More importantly, SPI-77 did not induce any 
of the toxicities commonly associated with platinum-based 
chemotherapy, such as nephrotoxicity and neutropenia. The 
formulation was shown to be well tolerated in patients at a 
dose range of 40–420 mg/m2. Side effects include mild gas-
trointestinal toxicity and mild anemia and muscle weakness. 
However, SPI-77 did not produce significant clinical response 
rates in several Phase II studies of patients with inoperable 
head and neck cancer, advanced non-small-cell lung cancer, 
or platinum-sensitive recurrence of ovarian cancer.56–58 
The lack of therapeutic efficacy is likely due to slow and 
inefficient release of platinum from SPI-77, as shown in 
preclinical studies.
Lipoplatin™ (Regulon Inc, Mountain View, CA, USA) 
is another cisplatin-containing long-circulating liposomal 
formulation. It is composed of soy phosphatidylcholine, 
cholesterol, dipalmitoyl phosphatidyl glycerol, and methoxy-
PEG-distearoyl phosphatidylethanolamine.59 The Lipoplatin 
formulation differs from SPI-77 in several ways. First, the 
loading method used in Lipoplatin is based on formation of 
reverse micelles between cisplatin and dipalmitoyl phosphati-
dyl glycerol, while the mechanism of cisplatin encapsulation 
in SPI-77 is totally passive. Second, the Lipoplatin formula-
tion uses anionic dipalmitoyl phosphatidyl glycerol lipid and 





neutral soy phosphatidylcholine lipid, whereas SPI-77 uses 
only neutral lipids. Third, the cisplatin to total lipid ratio is 
around 1:10 in the case of Lipoplatin, but SPI-77 has a much 
lower drug-to-lipid ratio of 1:70.60
Preclinical studies of Lipoplatin have shown lower 
nephrotoxicity and other side effects in mice and rats when 
compared with free cisplatin but with higher antitumor 
activity in breast MCF-7 and prostate LNCaP human tumor 
xenograft models.61,62 Treatment of dogs with Lipoplatin led 
to the conclusion that the drug can be safely administered to 
healthy dogs at dosages of up to 150 mg/m2 without the need 
for concurrent hydration protocols.63 In several Phase I, II, 
and III studies, Lipoplatin was shown to reduce renal toxic-
ity, peripheral neuropathy, ototoxicity, and myelotoxicity 
substantially but with enhanced or comparable efficacy to 
cisplatin.64 A 10–200-fold higher accumulation of Lipoplatin 
in solid tumors compared with adjacent normal tissues was 
found in patients.65 A Phase II study showed that Lipoplatin 
has lower renal toxicity as well as higher efficacy than cispla-
tin when combined with gemcitabine in advanced non-small 
cell lung cancer. A statistically significant higher response 
rate was also observed for a combination of Lipoplatin and 
paclitaxel when compared with the combination of cisplatin 
and paclitaxel in advanced non-small cell lung cancer in one 
randomized trial.66 However, there was no significant increase 
in survival. Lipoplatin has also been tested in a number of 
malignancies in several Phase II and III trials, including pan-
creatic cancer, head and neck cancer, and breast and gastric 
cancer, and preliminary results collected from these studies 
seem encouraging.59
Like Lipoplatin, Lipoxal™ is a liposomal formulation that 
carries oxaliplatin. In a Phase I study using six Lipoxal dose 
levels (100, 150, 200, 250, 300, and 350 mg/m2), no serious 
side effects were observed at doses of 100–250 mg/m2. Mild 
myelotoxicity, nausea, and grade 2–3 peripheral neuropathy 
were observed at doses of 300–350 mg/m2.67 With the reduc-
tion of many of the side effects of oxaliplatin, including 
myelotoxicity and gastrointestinal tract toxicity, and adequate 
antitumor activity, further clinical tests are warranted to dem-
onstrate the superiority of Lipoxal over free oxaliplatin.
The lack of antitumor activity of SPI-77 in clinical tri-
als suggests that hydrophilic chemotherapeutic agents like 
cisplatin cannot pass readily through the lipid membrane. 
The release of encapsulated drugs from liposome carriers 
upon their deposition in tumor tissues is critical to confer 
antitumor activity. LiPlaCis®, a novel liposomal formulation 
of cisplatin, is designed to be degraded by secretory phospho-
lipase A
2
. Given that secretory phospholipase A
2
 is relatively 
abundant in tumor sites, triggered drug release in tumor tissue 
is expected. As shown in a Phase I study, the pharmacokinetic 
profile of LiPlaCis could be best fitted into a two-compartment 
model with the initial half-life (t
1/2
α) reflecting the half-life 
of the intact liposome, and the secondary half-life (t
1/2
β) 
reflecting the half-life of plasma protein-bound platinum.68 
Although LiPlaCis was designed to be decomposed by secre-
tory phospholipase A
2
 specifically, other factors also contrib-
uted to the degradation of the particles because no correlation 
between the baseline levels of secretory phospholipase A
2
 
and the initial half-life of LiPlaCis was observed in patients. 
In addition, renal toxicity was not prevented by treatment by 
LiPlaCis and acute infusion reactions were observed in many 
patients even with premedication. The poor safety profile of 
LiPlaCis led to early cessation of this particular formulation 
in the Phase I stage and LiPlaCis requires reformulation to 
enable further development.
Preclinical liposomal formulations 
of platinum drugs with enhanced 
loading efficiency and active 
targeting capability
The clinical promise of liposomes in platinum drug delivery 
has encouraged many researchers to explore other possibili-
ties to enhance delivery efficiency further. New technologies 
and novel systems with improved encapsulation efficiency, 
drug loading capacity, and active targeting capability have 
been reported. Although many of these platforms are still in 
the early development stage, their in vitro and in vivo data 
show great promise for further clinical evaluations. Here we 
review several of these platforms.
By repeated freezing and thawing of a concentrated 
solution of cisplatin, Burger et al achieved significantly 
more efficient cisplatin encapsulation in liposomes.69 Their 
method involves hydration of a dry lipid film composed 
of equimolar amounts of dioleoyl-phosphatidylserine and 
dioleoyl- phosphatidylcholine with a buffered solution of 
5 mM cisplatin, followed by ten freeze-thaw cycles. This 
method generated nanocapsules with an unprecedented 
drug-to-lipid molar ratio of 0.5 ± 0.1, corresponding to about 
30 mM cisplatin, which far exceeded the solubility limit of 
cisplatin (8 mM). More impressively, in vitro cytotoxicity up 
to 1000-fold higher than that of the free drug was observed 
in human-derived ovarian (IGROV-1) tumor cells (Figure 1A 
and B). The authors attributed the formation of nanocapsules 
mainly to the solubility differences among neutral and charged 
aquo species of cisplatin, formation of ice phase during the 
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freeze-thaw cycles, and electrostatic interactions between cis-
platin aggregates and negatively charged lipids (Figure 1C).
Khiati et al reported another approach to encapsulating 
cisplatin efficiently into nucleoside lipids.70 Nucleoside lipids 
were used in this case to enhance the electrostatic interactions 
between negatively charged phospholipids and positively 
charged aquated platinum species in order to control and 
guide the precipitation and self-assembly process to form 
highly loaded and stable nanoparticles. This method involved 
a two-step layer-by-layer strategy, as shown in Figure 2A, 




sn-glycero-3-phosphate]) and further stabilization of the 
resulting anionic nanoparticles was realized by another 
bilayer of a cationic nucleoside lipid, DOTAU (2′,3′-dioleyl-
5′-deoxy-5′-trimethylammoniumuridine). It was shown 
that these particles were more efficiently internalized and 
more potent against a variety of cancer cell lines in vitro 
(Figure 2D and E). The present nucleolipid-based multilayer 
nanoparticles can thus overcome some of the disadvantages 
or limitations associated with other loading techniques, such 
as low drug-to-lipid ratio and instability of the assembly.
Aryal et al reported a novel platform for delivery of 
platinum-based drugs by using a synthetic phospholipid-
like platinum compound to allow its self-assembly into a 
liposome-like nanostructure (the Ptsome).71 Two hydrophobic 
acyl chains were attached to the Pt(II) center to endow 







































































Figure 1 Cytotoxicity towards human ovarian carcinoma cells. (A) Lipid suspension of cisplatin (cisPt-phosphatidylserine/phosphatidylcholine) (), conventional cisplatin 
(n), conventional cisplatin mixed with a blank lipid suspension (), and blank lipid suspension (dashed line). (B) variations on the standard protocol, omitting freeze-thaw 
(), omitting phosphatidylserine (). (C) Proposed mechanism of nanocapsule formation and cell interaction.
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Figure 2 (A) Layer-by-layer assembly of nanoparticles and chemical structures of the anionic and cationic lipids. (B) Transmission electron microscopic image of anionic 
nanoparticles (NP-) after uranyl acetate negative staining. (C) Transmission electron microscopic images of cationic nanoparticles (NP+) after uranyl acetate negative staining. 
Arrows indicate the multilayer. Scale bar, 50 nm. (D) Cytotoxic effect on IGROv-1 cancer cell line. (E) Comparison of cytotoxicity of cisplatin-loaded NP+ nanoparticles 
compared with free cisplatin in various human carcinoma cell lines.
Note: Adapted with permission from Khiati S, Luvino D, Oumzil K, Chauffert B, Camplo M, Barthélémy P. Nucleoside-lipid-based nanoparticles for cisplatin delivery. ACS Nano. 
2011;5(11):8649–8655. Copyright (2011) American Chemical Society.70





chloride and hydrazide moieties next to the platinum atom can 
readily form hydrogen bonds in aqueous solution to increase 
hydrophilicity. With the hydrophobic acyl chains, a liposomal 
structure should form with these compounds in a manner 
similar to the self-assembly of phospholipids into liposomes. 
After extruding the particle solution through a 100 nm pore 
size membrane, particles with a size of 100 nm in diameter was 
obtained. Scanning electron microscopic imaging confirmed 
formation of spherical Ptsomes with nearly uniform size. This 
delivery vehicle is unique in a sense, in that unlike other lipo-
somal delivery systems that utilize the aqueous space inside the 
liposome to store platinum drugs, the current study integrates 
drugs into the lipid composition, leading to an extremely high 
drug-to-lipid ratio. The Ptsome should also allow integration 
of other chemotherapeutics for combination therapy.
A novel chondroitin sulfate-binding cationic lipo-
some loaded with cisplatin was reported by Lee et al.72 
In their study, a new formulation of long-circulating 
PEG-coated liposomes comprising a new cationic lipid 
(3, 5- dipentadecycloxybenzamidine hydrochloride, TRX-20) 
was evaluated in vitro and in vivo against highly metastatic 
tumor cells expressing an increased level of chondroitin 
sulfate. It was shown that PEG-coated TRX-20 liposomes 
bound preferentially to certain chondroitin sulfates, such 
as B, D, and E. Confocal microscopy revealed efficient 
internalization of TRX-20 liposomes but not plain PEG lipo-
somes by human ACHN renal adenocarcinoma and murine 
LM8G5 osteosarcoma cells. The cisplatin-loaded TRX-20 
liposomes had higher cellular toxicity in vitro compared with 
cisplatin-PEG liposomes without TRX-20. Cisplatin-loaded 
TRX-20 liposomes, after intravenous injection, preferen-
tially accumulated in the liver and tumor region, inhibited 
tumor growth, and suppressed metastasis to the liver more 
effectively than plain cisplatin-loaded PEG liposomes or free 
cisplatin in an LM8G5 liver metastasis model. These novel 
cationic liposomes thus provide a promising vehicle to deliver 
many other anticancer drugs to solid tumors and metastases 
with enhanced expression of chondroitin sulfate.
Suzuki et al developed a transferrin-conjugated PEG lipo-
some formulation for tumor-selective delivery of oxaliplatin 
(L-OHP).73 This delivery system achieved a significantly 
longer blood circulation time compared with free oxaliplatin 
and higher L-OHP concentration in tumors compared with 
liposomes modified by PEG (Figure 3A and B). In a murine 
colon-26 tumor model, intravenous injection of L-OHP encap-
sulated within transferrin-conjugated PEG liposomes (L-OHP 
5 mg/kg) suppressed tumor growth more effectively than PEG 
liposomes, bare liposomes, and free L-OHP (Figure 3C). Given 
that transferrin receptors are overexpressed in various types 
of tumors, this targeting strategy should allow more efficient 
delivery of active agents to tumor sites through both passive 
targeting and active targeting pathways.
Lin and coworkers have developed a novel platform 
based on a nanoscale metal-organic framework or nanoscale 
coordination polymer for cancer-specific imaging and drug 
delivery.74–80 A nanoscale coordination polymer formulation 
based on a cisplatin prodrug, disuccinatocisplatin, and a 
La3+ metal ion was recently designed for targeted delivery 
to non-small cell lung cancer cell lines.81 The nanoscale 
coordination polymer particles were stabilized with a 
cholesterol/dioleoyl-phosphatidylcholine/1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-PEG lipid coating and 
further doped with a DSPE-PEG-anisamide conjugate to 
render them cancer-specific. This formulation showed higher 
potency than free cisplatin against non-small cell lung cancer 
cell lines, and enhanced uptake was confirmed by confocal 
microscopy and a competitive binding assay. The nanoscale 
coordination polymer delivery strategy is general and should 
allow incorporation of many other chemotherapeutics and 



















































































Figure 3 Plasma clearance (A) and biodistribution (B) of L-OHP, bare liposomes, PeG liposomes, and TF-PeG liposomes after intravenous injection. (C) Comparison of 
tumor growth suppression with free L-OHP and liposomes encapsulating L-OHP in a Colon-26 mouse model. 
Note: Reprinted from International Journal of Pharmaceutics. vol 346(1–2). Suzuki R, Takizawa T, Kuwata Y, et al. effective anti-tumor activity of oxaliplatin encapsulated in 
transferrin PeG-liposome, pages 143–150. Copyright (2008), with permission from elsevier.73
Abbreviations: PeG, polyethylene glycol; TF, transferrin; L-OHP, oxaliplatin; h, hours.
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Concluding remarks  
and perspectives
Nearly half a century of clinical research on platinum ana-
logs has yielded remarkable anticancer agents. However, of 
the thousands of platinum compounds, only a very small 
fraction has shown sufficient promise during preclinical 
evaluation to enter human clinical trials. Harnessing their 
potency while reducing unwanted side effects and expand-
ing the activity spectrum of platinum drugs while avoiding 
cross-resistance are important goals for the near future. A 
detailed understanding of how platinum drugs induce DNA 
damage, how the signals of DNA damage are transduced, how 
cell cycle arrest occurs, and how DNA repair and apoptosis 
are activated provide us with invaluable knowledge. With a 
better understanding of the mechanism of action, improved 
designs of new platinum-based compounds are expected. 
Among several emerging chemogenotherapeutic strategies, 
disruptions of certain pathways by RNA interference that 
modulate cellular sensitivity to platinum drugs are likely to 
lead to clinical benefits. The combination of platinum analogs 
and other chemotherapeutics, such as gemcitabine, paclitaxel, 
doxorubicin, and 5-fluorouracil, will also contribute to the 
increased spectrum of activity and anticancer efficacy.
At the same time, targeted delivery of platinum drugs 
with long-circulating liposomes also provides another 
efficient strategy to improve platinum drug efficacy with 
reduced toxicity. Liposomal drugs are highlighted for their 
abilities to “passively” accumulate at tumor sites via the 
enhanced permeability and retention effect and to reduce 
the side effects of encapsulated drugs by lowering unspecific 
cytotoxic drug distribution in normal tissues. These two fea-
tures endow liposomal drugs with an increased therapeutic 
ratio. The current liposomal formulations have primarily 
taken advantage of reduced systemic toxicity rather than 
increased efficacy. For example, the irreversible cardio-
toxicity induced by free doxorubicin could be significantly 
alleviated by entrapping the drug in liposomes.82,83 In order 
to increase drug bioavailability further and improve drug 
biodistribution at tumor sites, drug-loaded liposomes have 
been further modified with internalizing receptors, such as 
small molecules,84 sugar molecules,85 and antibodies86 or 
antibody fragments.87 However, liposomal formulations with 
active-targeting groups have yet to enter the clinic, owing to 
the high development costs (manufacturing, source of good, 
intellectual property) and batch-to-batch variation.
Despite the numerous successes in overcoming barri-
ers to liposomal drug delivery, it is still difficult to achieve 
an optimized balance between high and specific drug 
bioavailability in tumor tissue and prolonged liposome stabil-
ity in systemic circulation. Drug release from stable formula-
tions such as the Stealth® formulation is at best slow.88 The 
release of hydrophilic drugs such as cisplatin is dependent 
on degradation of the liposome vehicle. Therefore, a long 
systemic circulation and minimal side effects of chemotherapy 
could be achieved at the expense of lowered efficacy in vivo. 
More detailed knowledge is needed in order to reach a balance 
between obtaining stable formulations with long circulation 
times to minimize undesired systemic exposure and adequate 
drug release kinetics in order to achieve enhanced chemother-
apeutic efficacy.89 The development of liposomes from which 
drug release can be actively triggered is therefore of crucial 
importance for guiding liposomal drug delivery technologies 
to wide clinical applications in the treatment of cancer.
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